Findings With Abemaciclib Plus Tamoxifen in Advanced Breast Cancer

New Standards of Care for Advanced Prostate CancerПодробнее

Advanced Breast Cancer: Challenges in Pathways DevelopmentПодробнее

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim dataПодробнее

#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 studyПодробнее

Significance of the MONARCH 2 Findings for Abemaciclib in HR+/HER2- Breast CancerПодробнее

CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-nega...Подробнее

Emerging Role of Abemaciclib for HR+ Advanced Breast CancerПодробнее

Abemaciclib for HR+/HER2- advanced or metastatic breast cancerПодробнее

S2 Episode 1: Metastatic Endometrial Cancer: Hormonal Therapy Updates and Ways to Target and Trea...Подробнее

monarchE: adjuvant abemaciclib + endocrine therapy in patients with HR+, HER2- high-risk eBCПодробнее

Expert Perspectives: CDK 4/6 Inhibitors for ER+ Breast Cancer: Emerging Data and Future ImplicationsПодробнее

MonarchE results: Abemaciclib plus endocrine therapy in high-risk early breast cancerПодробнее

Continuous Abemaciclib Treatment Leads to Breast Cancer Inhibition | OncotargetПодробнее

Advanced Hormone Receptor-positive Breast CancerПодробнее

FDA Approval for AbemaciclibПодробнее

monarchE: adjuvant abemaciclib in HR+ breast cancerПодробнее

Dr. Tolaney on Abemaciclib Plus Pembrolizumab for HR+, HER2- Breast CancerПодробнее

MONARCH 2: abemaciclib added to fulvestrant shows OS benefit in HR+/HER2- advanced breast cancerПодробнее

4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BCПодробнее

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared...Подробнее